Caris Life Sciences, Inc. (Ticker: CAI US) is a United States company specializing in AI-based precision medicine and cancer diagnostics. Caris Life Sciences plans to list on the Nasdaq on Wednesday, June 18, 2025, offering 23.5 million shares priced between $16.00 and $18.00 and aiming to raise up to $423.5 million. The IPO is reportedly targeting a valuation of up to $5.3 billion, a notable decrease from its $7.8 billion valuation in a 2021 funding round. The company plans to use the net proceeds for general corporate purposes, including working capital, operating expenses, and capital expenditures. Founded in 2008, Caris uses tumor and blood-based profiling to help select appropriate cancer therapies. The lead underwriters for the offering are reportedly BofA Securities, J.P. Morgan, Goldman Sachs, and Citigroup.